Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 48
Filtrar
1.
Curr Opin Allergy Clin Immunol ; 21(4): 346-354, 2021 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-34074874

RESUMEN

PURPOSE OF REVIEW: To review the most recent literature studying the classifications, immunochemistry, and crossreactivity of allergy reactions to cephalosporins. RECENT FINDINGS: Over the last five years, research interest has focused on three areas related to cephalosporin allergy: cross-reactivity among cephalosporins and with other beta-lactams; the incidence of adverse reactions in penicillin allergy patients or in reported penicillin allergy labels; and new cephalosporins structures involved in the immunological recognition. SUMMARY: Meta-analysis of a substantial number of studies shows that cephalosporins are safer than previously thought. Evidence supports two main conclusions in that regard. First, there is a relatively low percentage of cross-reactivity between cephalosporins and other beta-lactams with penicillins in penicillin allergy patients. Second, there is a very low incidence of allergy reactions in nonselected as well as in selected penicillin allergy patients when cephalosporins are used prior to surgical intervention.On the other hand, few structures have been discovered related to the immune mechanism of cephalosporin allergy reactions, and these are far from being ready to use in clinical practice.


Asunto(s)
Antibacterianos , Cefalosporinas , Hipersensibilidad a las Drogas , Antibacterianos/efectos adversos , Antibacterianos/clasificación , Cefalosporinas/efectos adversos , Cefalosporinas/clasificación , Reacciones Cruzadas , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/tratamiento farmacológico , Hipersensibilidad a las Drogas/epidemiología , Humanos , Penicilinas/efectos adversos , Penicilinas/clasificación , Pruebas Cutáneas , beta-Lactamas/efectos adversos , beta-Lactamas/clasificación
2.
Antimicrob Resist Infect Control ; 9(1): 37, 2020 03 03.
Artículo en Inglés | MEDLINE | ID: mdl-32122406

RESUMEN

BACKGROUND: The overuse of antimicrobials in food animals and the subsequent contamination of the environment have been associated with development and spread of antimicrobial resistance. This review presents information on antimicrobial use, resistance and status of surveillance systems in food animals and the environment in Africa. METHODS: Information was searched through PubMed, Google Scholar, Web of Science, and African Journal Online databases. Full-length original research and review articles on antimicrobial use, prevalence of AMR from Africa covering a period from 2005 to 2018 were examined. The articles were scrutinized to extract information on the antimicrobial use, resistance and surveillance systems. RESULTS: A total of 200 articles were recovered. Of these, 176 studies were included in the review while 24 articles were excluded because they were not relevant to antimicrobial use and/or resistance in food animals and the environment. The percentage of farms using antimicrobials in animal production ranged from 77.6% in Nigeria to 100% in Tanzania, Cameroon, Zambia, Ghana and Egypt. The most antibiotics used were tetracycline, aminoglycoside and penicillin groups. The percentage of multi drug resistant isolates ranged from 20% in Nigeria to 100% in South Africa, Zimbabwe and Tunisia. In the environment, percentage of multi drug resistant isolates ranged from 33.3% in South Africa to 100% in Algeria. None of the countries documented national antimicrobial use and resistance surveillance system in animals. CONCLUSION: There is high level of antimicrobial use, especially tetracycline, aminoglycoside and penicillin in animal production systems in Africa. This is likely to escalate the already high prevalence of antimicrobial resistance and multi drug resistance in the continent. This, coupled with weak antimicrobial resistance surveillance systems in the region is a great concern to the animals, environment and humans as well.


Asunto(s)
Antibacterianos/administración & dosificación , Farmacorresistencia Bacteriana Múltiple , África/epidemiología , Aminoglicósidos/administración & dosificación , Aminoglicósidos/clasificación , Aminoglicósidos/farmacología , Animales , Antibacterianos/clasificación , Antibacterianos/farmacología , Programas de Optimización del Uso de los Antimicrobianos , Microbiología de Alimentos , Penicilinas/administración & dosificación , Penicilinas/clasificación , Penicilinas/farmacología , Vigilancia de la Población , Tetraciclina/administración & dosificación , Tetraciclina/clasificación , Tetraciclina/farmacología
3.
Ann Allergy Asthma Immunol ; 108(2): 88-93, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22289726

RESUMEN

BACKGROUND: Population-based data on the demographics and clinical characteristics of patients with multiple unrelated drug class intolerances noted in their medical records are lacking. OBJECTIVES: To provide population-based drug "allergy" incidence rates and prevalence, and to identify individuals with multiple drug intolerance syndrome (MDIS) defined by 3 or more unrelated drug class "allergies," and to provide demographic and clinical information on MDIS cases. METHODS: Electronic medical record data from 2,375,424 Kaiser Permanente Southern California health plan members who had a health care visit and at least 11 months of health care coverage during 2009 were reviewed. Population-based drug "allergy" incidence rates and prevalence were determined for 23 unrelated medication classes. RESULTS: On January 1, 2009, 478,283 (20.1%) health plan members had at least one reported "allergy." Individuals with a history of at least 1 "allergy" and females, in general, reported higher population-based new "allergy" incidence rates. Multiple drug intolerance syndrome was present in 49,582 (2.1%). The MDIS cases were significantly older, 62.4 ± 16.1 years; heavier, body mass index 29.3 ± 7.1; and likely to be female, 84.9%, compared with average health plan members. They had high rates of health care utilization, medication usage, and new drug "allergy" incidence. They sought medical attention for common nonmorbid conditions. CONCLUSIONS: Multiple drug intolerance syndrome is in part iatrogenic. It is associated with overweight elderly women who have high rates of health care and medication usage. Urticarial syndromes only explain a small fraction of MDIS cases. Multiple drug intolerance syndrome is associated with anxiety, but not predominately with immunoglobulin E (IgE)-mediated allergy or life-threatening illness. Multiple drug intolerance syndrome can be managed by medication avoidance and judicious rechallenge.


Asunto(s)
Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/epidemiología , Planes de Salud de Prepago/estadística & datos numéricos , Adulto , Factores de Edad , Anciano , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Inhibidores de la Enzima Convertidora de Angiotensina/clasificación , California/epidemiología , Hipersensibilidad a las Drogas/tratamiento farmacológico , Registros Electrónicos de Salud , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Narcóticos/efectos adversos , Narcóticos/clasificación , Penicilinas/efectos adversos , Penicilinas/clasificación , Prevalencia , Factores de Riesgo , Factores Sexuales , Síndrome
4.
J Pediatr (Rio J) ; 85(5): 421-5, 2009.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-19830357

RESUMEN

OBJECTIVE: To evaluate the impact of new penicillin susceptibility breakpoints on resistance rates of pneumococcal strains collected from children with pneumonia. METHODS: Pneumococcal strains collected from patients admitted with pneumonia were isolated at the clinical analysis lab of Hospital de Clínicas de Uberlândia, Uberlândia, Brazil, and sent to Instituto Adolfo Lutz, São Paulo, Brazil, for further identification, serotyping and determination of antimicrobial susceptibility. RESULTS: From April 1999 to December 2008, 330 strains of pneumococcus were sent to Instituto Adolfo Lutz; of these, 195 (59%) were collected from patients with pneumonia. One hundred strains collected from patients < or = 12 years old were analyzed. The patients' age ranged from 1 to 12.6 years old (with mean age of 2.4 and median of 1.7 years). Forty-seven patients were male. The strains were isolated from blood (42%) and pleural fluid (58%). There were 35 oxacillin-resistant strains: according to the criteria defined by the Clinical and Laboratory Standards Institute (CLSI) in 2007 [minimum inhibitory concentration (MIC) < or = 0.06 microg/mL for susceptibility (S), 0.12 to 1 microg/mL for intermediate resistance (IR), and > or = 2 microg/mL for full resistance (FR)], 22 strains had IR and 11 strains had FR. According to the current breakpoints defined by the CLSI in 2008 (< or = 2 microg/mL for S, 4 microg/mL for IR and > or = 8 microg/mL for FR), only one strain had IR to penicillin. There was resistance to co-trimoxazole (80%), tetracycline (21%), erythromycin (13%), clindamycin (13%), and ceftriaxone (one strain simultaneously resistant to penicillin). CONCLUSIONS: When the new breakpoints for in vitro susceptibility were applied, penicillin resistance rates dropped 97%, from 33 to 1%.


Asunto(s)
Antibacterianos/farmacología , Resistencia a las Penicilinas , Penicilinas/farmacología , Neumonía Neumocócica/microbiología , Streptococcus pneumoniae/efectos de los fármacos , Adolescente , Antibacterianos/clasificación , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Pruebas de Sensibilidad Microbiana , Penicilinas/clasificación , Cavidad Pleural/microbiología , Neumonía Neumocócica/sangre , Streptococcus pneumoniae/aislamiento & purificación
5.
J. pediatr. (Rio J.) ; 85(5): 421-425, set.-out. 2009. tab
Artículo en Portugués | LILACS | ID: lil-530118

RESUMEN

OBJETIVO: Avaliar impacto dos novos pontos de corte de sensibilidade à penicilina nas taxas de resistência de cepas de pneumococo obtidas de crianças com pneumonia. MÉTODOS: Cepas de pneumococo isoladas no laboratório de análises clínicas do Hospital de Clínicas de Uberlândia, Uberlândia (MG), a partir de amostras de pacientes internados foram enviadas ao Instituto Adolfo Lutz, Sao Paulo (SP), para confirmação da identificação, sorotipagem e determinação da sensibilidade aos antimicrobianos. RESULTADOS: De abril de 1999 a dezembro de 2008 foram enviadas ao Instituto Adolfo Lutz 330 cepas de pneumococo, sendo 195 (59 por cento) provenientes de pacientes com diagnóstico de pneumonia. Destas, foram analisadas 100 cepas de pacientes com idade ≤ 12 anos; a idade dos pacientes variou de 1 a 12,6 anos, com média de 2,4 e mediana de 1,7 anos; 47 pacientes eram do sexo masculino; as fontes de recuperação foram sangue (42 por cento) e líquido pleural (58 por cento). Foram detectadas 35 cepas oxacilina-resistentes: segundo os critérios do Clinical and Laboratory Standards Institute (CLSI) de 2007 [concentração inibitória mínima (CIM) ≤ 0,06 µg/mL para sensibilidade (S), 0,12 a 1 µg/mL para resistência intermediária (RI) e ≥ 2 µg/mL para resistência plena (RP)], 22 cepas apresentaram RI e 11, RP para penicilina. De acordo com os critérios atuais do CLSI de 2008 (≤ 2 µg/mL para S, 4 µg/mL para RI e ≥ 8 µg/mL para RP) apenas uma cepa confirmou RI à penicilina. Detectou-se resistência a cotrimoxazol (80 por cento), tetraciclina (21 por cento), eritromicina (13 por cento), clindamicina (13 por cento) e ceftriaxona (uma cepa, simultaneamente resistente a penicilina). CONCLUSÕES: Com a aplicação dos novos pontos de corte para sensibilidade in vitro, as taxas de resistência a penicilina caíram 97 por cento, de 33 para 1 por cento.


OBJECTIVE: To evaluate the impact of new penicillin susceptibility breakpoints on resistance rates of pneumococcal strains collected from children with pneumonia. METHODS: Pneumococcal strains collected from patients admitted with pneumonia were isolated at the clinical analysis lab of Hospital de Clínicas de Uberlândia, Uberlândia, Brazil, and sent to Instituto Adolfo Lutz, São Paulo, Brazil, for further identification, serotyping and determination of antimicrobial susceptibility. RESULTS: From April 1999 to December 2008, 330 strains of pneumococcus were sent to Instituto Adolfo Lutz; of these, 195 (59 percent) were collected from patients with pneumonia. One hundred strains collected from patients ≤ 12 years old were analyzed. The patients' age ranged from 1 to 12.6 years old (with mean age of 2.4 and median of 1.7 years). Forty-seven patients were male. The strains were isolated from blood (42 percent) and pleural fluid (58 percent). There were 35 oxacillin-resistant strains: according to the criteria defined by the Clinical and Laboratory Standards Institute (CLSI) in 2007 [minimum inhibitory concentration (MIC) ≤ 0.06 µg/mL for susceptibility (S), 0.12 to 1 µg/mL for intermediate resistance (IR), and ≥ 2 µg/mL for full resistance (FR)], 22 strains had IR and 11 strains had FR. According to the current breakpoints defined by the CLSI in 2008 (≤ 2 µg/mL for S, 4 µg/mL for IR and ≥ 8 µg/mL for FR), only one strain had IR to penicillin. There was resistance to co-trimoxazole (80 percent), tetracycline (21 percent), erythromycin (13 percent), clindamycin (13 percent), and ceftriaxone (one strain simultaneously resistant to penicillin). CONCLUSIONS: When the new breakpoints for in vitro susceptibility were applied, penicillin resistance rates dropped 97 percent, from 33 to 1 percent.


Asunto(s)
Adolescente , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Antibacterianos/farmacología , Resistencia a las Penicilinas , Penicilinas/farmacología , Neumonía Neumocócica/microbiología , Streptococcus pneumoniae/efectos de los fármacos , Antibacterianos/clasificación , Pruebas de Sensibilidad Microbiana , Penicilinas/clasificación , Cavidad Pleural/microbiología , Neumonía Neumocócica/sangre , Streptococcus pneumoniae/aislamiento & purificación
6.
Medisur ; 7(4)2009. tab, graf
Artículo en Español | CUMED | ID: cum-40887

RESUMEN

Fundamento: Las penicilinas se diferencian estructuralmente entre sí por las cadenas laterales. Al mismo tiempo, poseen diferencias en su acciónfarmacológica, que pueden estar asociadas a modificaciones inducidas en el anillo betalactámico y/o efectos localizados en las propias cadenas. Esclarecerlo, sería un aporte en la búsqueda de las características estructurales y electrónicas más adecuadas para el diseño de mejores penicilinas. Objetivo: Comparar laspropiedades estructurales, densidades de cargas atómicas y los orbitales de frontera de cuatro penicilinas(bencilpenicilina, fenoximetilpenicilina, ampicilina y amoxicilina) mediante la modelación de la Teoría del Funcional de la Densidad. Método: Se optimizaron las estructuras moleculares con cálculos semiempíricos PM3. Las propiedades moleculares se calcularon según laTeoría del Funcional de la Densidad, a un nivel B3LYP/6-31G (d). Se analizaron las densidades de cargasatómicas y los orbitales de frontera. Se evaluó el efecto de los sustituyentes sobre las propiedades del anillobetalactámico. Resultados: Los parámetros estructurales del anillo betalactámico no variaron comoconsecuencia de las modificaciones en la cadena lateral unida al carbono 6. El anillo presentó una marcada tendencia a la planaridad. Tampoco se observaronvariaciones en la densidad de carga positiva del carbono carbonílico. Conclusiones: La estructura y propiedades electrónicas del anillo betalactámico, base estructural deestos antibióticos, no tienen modificaciones significativas entre las penicilinas modeladas(AU)


Background: Penicillins differ structurally among themselves by the lateral chains. At the same time, theyhave differences in their pharmacological action that canbe associated to modifications included in the betalactamic ring and/or effects localized in the same chains. Making it clear would be a contribution to thesearch of the most adequate structural and electronic characteristics to design better penicillins. Objective:To compare structural properties, density of the atomic charges and the frontier orbitals of four penicillins: bencylpenicillin, phenoxymethylpenicillin, ampicillin andamoxicillin. Method: The molecular structures were optimized with PM3 semiempirical calculi. The molecularproperties were calculated according to the Density Functional Theory, at a B3LYP/6-31G(d) level. The density of the atomic charges and the frontier orbitals were analyzed. The effect of the substituents on the properties of the betalactamic ring was evaluated. Results: The structural parameters of the betalactamic ring do not change as consequence of the modifications in the lateral chain linked to carbon 6. The ring has a marked tendency to planarity. There are no variations in the density of the positive charge of the carbonylic carbon. Conclusions: The structures and electronic properties of the betalactamic ring, structural basis of these antibiotics, do not have significant modifications among modelled penicillins(AU)


Asunto(s)
Humanos , Penicilinas/química , Penicilinas/clasificación , Penicilinas/farmacología , Estructura Molecular
8.
Chest ; 132(2): 447-55, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17573508

RESUMEN

BACKGROUND: Although acute exacerbations of chronic bronchitis (AECBs) are common, there has been no metaanalysis that focused on the optimum regimen. METHODS: To evaluate the comparative effectiveness and safety of first-line antimicrobial agents (ie, amoxicillin, ampicillin, pivampicillin, trimethoprim/sulfamethoxazole, and doxycycline) and second-line antimicrobial agents (ie, amoxicillin/clavulanic acid, macrolides, second-generation or third-generation cephalosporins, and quinolones) for the treatment of patients with AECB, in an era of increasing antimicrobial resistance among the microbes responsible for AECB, we performed a metaanalysis of randomized controlled trials (RCTs) retrieved through searches of the PubMed and the Cochrane databases. RESULTS: Twelve RCTs were included in the metaanalysis. First-line antibiotics were associated with lower treatment success compared to second-line antibiotics in the clinically evaluable patients (odds ratio [OR], 0.51; 95% confidence interval [CI], 0.34 to 0.75). There were no differences among the compared regimens regarding mortality (OR, 0.64; 95% CI, 0.25 to 1.66) or treatment success (OR, 0.56; 95% CI, 0.22 to 1.43) in microbiologically evaluable patients, or adverse effects in general (OR, 0.75; 95% CI, 0.39 to 1.45) or diarrhea in particular (OR, 1.58; 95% CI, 0.74 to 3.35). CONCLUSIONS: Compared to first-line antibiotics, second-line antibiotics are more effective, but not less safe, when administered to patients with AECB. The available data did not allow for stratified analyses according to the presence of risk factors for poor outcome, such as increased age, impaired lung function, airway obstruction, and frequency of exacerbations; this fact should be taken into consideration when interpreting the findings of this metaanalysis.


Asunto(s)
Bronquitis Crónica/tratamiento farmacológico , Macrólidos/uso terapéutico , Penicilinas/uso terapéutico , Intervalos de Confianza , Humanos , Macrólidos/clasificación , Oportunidad Relativa , Penicilinas/clasificación , Ensayos Clínicos Controlados Aleatorios como Asunto , Recurrencia , Resultado del Tratamiento
9.
Col. med. estado Táchira ; 14(3): 39-41, jul.-sept. 2005. ilus
Artículo en Español | LILACS | ID: lil-531048

RESUMEN

Este trabajo de investigación se basó en los efectos de la penicilina cristalina en pediatría Hospital "Dr. Samuel Darío Maldonado" San Antonio Táchira, tiene como finalidad demostrar que a pesar de tener más de 50 años de haber sido descubierta la penicilina, aún existe susceptibilidad de los agentes etiológicos de las neumonías en niños.


Asunto(s)
Humanos , Masculino , Adolescente , Antibacterianos/análisis , Dolor en el Pecho/diagnóstico , Escalofríos/diagnóstico , Fiebre/diagnóstico , Neumonía/diagnóstico , Neumonía/patología , Neumonía/terapia , Penicilinas/administración & dosificación , Penicilinas/clasificación , Penicilinas/uso terapéutico , Pediatría , Pared Celular/parasitología , Penicilina G/farmacología , Respiración
10.
In. Morejón García, Moisés; Salup Díaz, Rosa Regla; Cué Brugueras, Manuel. Actualización en antimicrobianos sistemáticos. La Habana, Ecimed, 2005. .
Monografía en Español | CUMED | ID: cum-39768
11.
In. Morejón García, Moisés; Salup Díaz, Rosa Regla; Cué Brugueras, Manuel. Actualización en antimicrobianos sistemáticos. La Habana, Ecimed, 2005. .
Monografía en Español | CUMED | ID: cum-39767
12.
Adv Biochem Eng Biotechnol ; 88: 45-90, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15719552

RESUMEN

The beta-lactam antibiotic penicillin is one of the mainly used antibiotics for the therapy of infectious diseases. It is produced as end product by some filamentous fungi only, most notably by Aspergillus (Emericella) nidulans and Penicillium chrysogenum. The penicillin biosynthesis is catalysed by three enzymes which are encoded by the following three genes: acvA (pcbAB), ipnA (pcbC) and aatA (penDE). The genes are organised into a gene cluster. Although the production of secondary metabolites as penicillin is not essential for the direct survival of the producing organisms, several studies indicated that the penicillin biosynthesis genes are controlled by a complex regulatory network, e.g. by the ambient pH, carbon source, amino acids, nitrogen etc. A comparison with the regulatory mechanisms (regulatory proteins and DNA elements) involved in the regulation of genes of primary metabolism in lower eukaryotes is thus of great interest. This has already led to the elucidation of new regulatory mechanisms. Positively acting regulators have been identified such as the pH dependent transcriptional regulator PACC, the CCAAT-binding complex AnCF and seem also to be represented by recessive trans-acting mutations of A. nidulans (prgA1, prgB1, npeE1) and R chrysogenum (carried by mutants Npe2 and Npe3). In addition, repressors like AnBH1 and VeA are involved in the regulation. Furthermore, such investigations have contributed to the elucidation of signals leading to the production of penicillin and can be expected to have a major impact on rational strain improvement programs.


Asunto(s)
Aspergillus nidulans/metabolismo , Proteínas Fúngicas/metabolismo , Regulación de la Expresión Génica/fisiología , Penicilinas/biosíntesis , Penicilinas/química , Penicillium chrysogenum/metabolismo , Factores de Transcripción/metabolismo , Antibacterianos/biosíntesis , Antibacterianos/química , Antibacterianos/clasificación , Aspergillus nidulans/clasificación , Aspergillus nidulans/genética , Proteínas Fúngicas/genética , Mejoramiento Genético/métodos , Penicilinas/clasificación , Penicillium chrysogenum/clasificación , Penicillium chrysogenum/genética , Transducción de Señal/fisiología , Especificidad de la Especie , Factores de Transcripción/genética , beta-Lactamas/química , beta-Lactamas/metabolismo
14.
Enferm Infecc Microbiol Clin ; 21(1): 42-55, 2003 Jan.
Artículo en Español | MEDLINE | ID: mdl-12550043

RESUMEN

Betalactams, which act by inhibiting the last phase of bacterial cell wall synthesis, constitute the largest family of antimicrobial agents and the most extensively used in current clinical practice. These drug have a slow bactericidal action that is relatively independent of plasma concentrations, little toxicity and a broad therapeutic margin. Their spectrum has increased over the years with the incorporation of new molecules having greater activity against gram-negative bacilli. Nevertheless, the progressive emergence of acquired resistance has limited the empirical use of betalactams and their efficacy in certain situations. Despite this problem, penicillin is still the treatment of choice for a large number of classic infections, cephalosporins are widely used in surgical prophylaxis and severe community-acquired infections, carbapenems are the choice for mixed nosocomial and multiresistant bacterial infections and betalactamase inhibitors permit the effective use of amino- and ureido-penicillins in highly significant infections.


Asunto(s)
Antibacterianos/uso terapéutico , Antibacterianos/química , Antibacterianos/farmacología , Carbapenémicos/farmacología , Carbapenémicos/uso terapéutico , Cefalosporinas/farmacología , Cefalosporinas/uso terapéutico , Endocarditis Bacteriana/tratamiento farmacológico , Humanos , Estructura Molecular , Monobactamas/farmacología , Monobactamas/uso terapéutico , Neutropenia/tratamiento farmacológico , Penicilinas/clasificación , Penicilinas/farmacología , Penicilinas/uso terapéutico , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones de los Tejidos Blandos/tratamiento farmacológico , Infecciones Cutáneas Estafilocócicas/tratamiento farmacológico , Infecciones Urinarias/tratamiento farmacológico , Resistencia betalactámica , Inhibidores de beta-Lactamasas
15.
J Midwifery Womens Health ; 47(6): 426-34, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12484664

RESUMEN

The penicillin family is one of the most valuable groups of antibiotics in primary care. They are bacteriocidal, well distributed, and highly efficacious against susceptible organisms. Development of synthetic penicillins has both broadened the spectrum of activity and enhanced the efficacy of these medications. However, emergence of resistant bacterial strains has limited the usefulness of penicillins in recent years. Nonetheless, penicillins remain the drugs of choice for many mild, localized soft tissue infections and are particularly important in specific situations during pregnancy. History of penicillin allergy does not necessarily prohibit the use of penicillin. In patients with a self-reported history of allergy, skin testing often fails to elicit signs of a true allergy to penicillin. Failure to prescribe penicillin for penicillin-sensitive infections in these patients contributes to the development of bacterial resistance. This paper provides a review of the modes of action, spectrums of activity, adverse effects for the various classes of penicillin most often used in primary care and highlights clinical issues in managing women with penicillin allergy.


Asunto(s)
Penicilinas/farmacología , Penicilinas/uso terapéutico , Anafilaxia/diagnóstico , Anafilaxia/terapia , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Cefalosporinas/farmacología , Reacciones Cruzadas , Hipersensibilidad a las Drogas/clasificación , Hipersensibilidad a las Drogas/diagnóstico , Quimioterapia Combinada/farmacología , Quimioterapia Combinada/uso terapéutico , Femenino , Humanos , Ácido Penicilánico/farmacología , Ácido Penicilánico/uso terapéutico , Penicilinas/clasificación , Inhibidores de beta-Lactamasas
16.
Allergy ; 57(12): 1151-8, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12464043

RESUMEN

BACKGROUND: Long-term follow-up data on adverse drug reactions after oral antibiotic use in penicillin allergy history positive individuals with penicillin skin test done in advance of need are rare. METHODS: Oral antibiotic associated adverse drug reactions in 83 penicillin skin test positive individuals were compared to a sex, age, and length of follow-up matched sample of 166 penicillin skin test negative individuals, all of whom had at least one post penicillin skin test oral antibiotic. The mean post penicillin skin test follow-up interval was 34.5 +/- 16.6 months. There were 1655 total oral antibiotic exposures. RESULTS: In penicillin skin test positive individuals, the adverse drug reaction rate was not significantly different with cephalosporin or non-beta-lactam use (P = 0.12). In penicillin skin test negative individuals the adverse drug reaction rate was significantly lower with cephalosporin vs. non-beta-lactam use (P = 0.005). Penicillin was safely used in penicillin skin test negative individuals. Overall cephalosporins caused fewer adverse drug reactions independent of penicillin skin test status (P = 0.005). CONCLUSIONS: Penicillin skin testing was only able to predict penicillin associated adverse drug reactions in penicillin skin test positive individuals. Excluding accidental penicillin exposure in penicillin skin test positive individuals, non-beta-lactams were associated with adverse drug reactions more often than penicillins or cephalosporins, independent of the penicillin skin test result. Cephalosporins were used as or more safely than non-beta-lactams in both penicillin skin test positive and negative individuals.


Asunto(s)
Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/etiología , Penicilinas/administración & dosificación , Penicilinas/efectos adversos , Pruebas Cutáneas , Administración Oral , Adolescente , Adulto , California , Estudios de Casos y Controles , Cefalosporinas/administración & dosificación , Cefalosporinas/efectos adversos , Cefalosporinas/clasificación , Niño , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Humanos , Hipersensibilidad Inmediata/inducido químicamente , Hipersensibilidad Inmediata/diagnóstico , Masculino , Persona de Mediana Edad , Penicilinas/clasificación , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Estadística como Asunto , Tiempo , Insuficiencia del Tratamiento
18.
Vet Clin North Am Small Anim Pract ; 28(2): 215-31, 1998 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9556846

RESUMEN

This article will focus on the drugs for which there has been a recent or renewed interest in veterinary medicine. Some of these are new drugs that were recently introduced. Others discussed may be human-label drugs for which there has been recent interest in veterinary medicine because of the need for a more active drug or convenient regimen. For drugs such as the aminoglycosides included here, recent information has provided us with updated dosage guidelines.


Asunto(s)
Antiinfecciosos/uso terapéutico , Infecciones Bacterianas/veterinaria , Aminoglicósidos , Animales , Antibacterianos/efectos adversos , Antibacterianos/clasificación , Antibacterianos/uso terapéutico , Antiinfecciosos/clasificación , Infecciones Bacterianas/tratamiento farmacológico , Carbapenémicos/clasificación , Carbapenémicos/uso terapéutico , Cefalosporinas/clasificación , Cefalosporinas/uso terapéutico , Fluoroquinolonas , Glicopéptidos , Macrólidos , Penicilinas/clasificación , Penicilinas/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA